Patents by Inventor Sherry J. Logusch

Sherry J. Logusch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 7195917
    Abstract: Methods and materials are disclosed for the inhibition and control of gibberellic acid levels. In particular, nucleic acid sequences of copalyl diphosphate synthase. 3-? hydroxylase, and 2-oxidase and additional nucleic acid sequences are disclosed. Gibberellic acid levels may be inhibited or controlled by preparation of a chimeric expression construct capable of expressing a RNA or protein product which suppresses the gibberellin biosynthetic pathway sequence, diverts substrates from the pathway or degrades pathway substrates or products. The sequence is preferably a copalyl diphosphate synthase sequence, a 3?-hydroxylase sequence, a 2-oxidase sequence, a phytoene synthase sequence, a C20-oxidase sequence, and a 2?,3?-hydroxylase sequence. Administration of a complementing agent, preferably a gibberellin or gibberellin precursor or intermediate restores bioactivity.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: March 27, 2007
    Assignee: Monsanto Technology LLC
    Inventors: Sherri M. Brown, Tedd D. Elich, Gregory R. Heck, Ganesh M. Kishore, Eugene W. Logusch, Sherry J. Logusch, Kenneth J. Piller, Sudabathula Rao, Joel E. Ream, Scott R. Baerson
  • Patent number: 6723897
    Abstract: Methods and materials are disclosed for the inhibition and control of gibberellic acid levels. In particular, nucleic acid sequences of copalyl diphosphate synthase, 3-&bgr; hydroxylase, and 2-oxidase and additional nucleic acid sequences are disclosed. Gibberellic acid levels may be inhibited or controlled by preparation of a chimeric expression construct capable of expressing antisense RNA which suppresses the gibberellin biosynthetic pathway sequence. The antisense sequence is the complement of a copalyl diphosphate synthase sequence, a 3&bgr;-hydroxylase sequence, or a C20-oxidase sequence. Administration of a complementing agent, preferably a gibberellin or gibberellin precursor or intermediate restores bioactivity.
    Type: Grant
    Filed: August 10, 1999
    Date of Patent: April 20, 2004
    Assignee: Monsanto Technology, LLC
    Inventors: Sherri M. Brown, Tedd D. Elich, Gregory R. Heck, Ganesh M. Kishore, Eugene W. Logusch, Sherry J. Logusch, Kenneth J. Piller, Sudabathula Rao, Joel E. Ream, Scott R. Baerson
  • Publication number: 20030233679
    Abstract: Methods and materials are disclosed for the inhibition and control of gibberellic acid levels. In particular, nucleic acid sequences of copalyl diphosphate synthase. 3-&bgr; hydroxylase, and 2-oxidase and additional nucleic acid sequences are disclosed. Gibberellic acid levels may be inhibited or controlled by preparation of a chimeric expression construct capable of expressing a RNA or protein product which suppresses the gibberellin biosynthetic pathway sequence, diverts substrates from the pathway or degrades pathway substrates or products. The sequence is preferably a copalyl diphosphate synthase sequence, a 3&bgr;-hydroxylase sequence, a 2-oxidase sequence, a phytoene synthase sequence, a C20-oxidase sequence, and a 2&bgr;,3&bgr;-hydroxylase sequence. Administration of a complementing agent, preferably a gibberellin or gibberellin precursor or intermediate restores bioactivity.
    Type: Application
    Filed: March 27, 2003
    Publication date: December 18, 2003
    Applicant: Monsanto Technology LLC.
    Inventors: Sherri M. Brown, Tedd D. Elich, Gregory R. Heck, Ganesh M. Kishore, Eugene W. Logusch, Sherry J. Logusch, Kenneth J. Piller, Sudabathula Rao, Joel E. Ream, Scott R. Baerson
  • Publication number: 20020053095
    Abstract: Methods and materials are disclosed for the inhibition and control of gibberellic acid levels. In particular, nucleic acid sequences of copalyl diphosphate synthase, 3-&bgr; hydroxylase, and 2-oxidase and additional nucleic acid sequences are disclosed. Gibberellic acid levels may be inhibited or controlled by preparation of a chimeric expression construct capable of expressing a RNA or protein product which suppresses the gibberellin biosynthetic pathway sequence, diverts substrates from the pathway or degrades pathway substrates or products. The sequence is preferably a copalyl diphosphate synthase sequence, a 3&bgr;-hydroxylase sequence, a 2-oxidase sequence, a phytoene synthase sequence, a C20-oxidase sequence, and a 2&bgr;,3&bgr;-hydroxylase sequence. Administration of a complementing agent, preferably a gibberellin or gibberellin precursor or intermediate restores bioactivity.
    Type: Application
    Filed: August 10, 1999
    Publication date: May 2, 2002
    Applicant: ARNOLD WHITE & DURKEE
    Inventors: SHERRI M. BROWN, TEDD D. ELICH, GREGORY R. HECK, GANESH M. KISHORE, EUGENE W. LOGUSCH, SHERRY J. LOGUSCH, KENNETH J. PILLER, SUDABATHULA RAO, JOEL E. REAM